Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispeci...
What are the regulatory and commercial milestones for Imdelltra, and how could delays or approvals impact the expected return on this deal?
What are the projected royalty streams from Imdelltra and how do they compare to Royalty Pharma’s existing portfolio and peers in the royalty‑fund sector?
How will the acquisition and upfront $885 million payment affect Royalty Pharma’s cash balance and valuation in the short term?
1 day ago